MOLECULAR EXPRESS, INC — Department of Health and Human Services SBIR Phase I: NIAID
MOLECULAR EXPRESS, INC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $599,596
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NIAID
- Solicitation
- PA20-260
- NAICS
- —
- Place of performance
- CA
- Period
- 2022-02-18 → 2024-01-31
Description
Project SummaryThe principal goal of this project is to develop a VesiVax®-based vaccine against Neisseria gonorrhoeae (Ng). The studies proposed in this SBIR Phase I application will be focused on co-formulating an newly identified surface-displayed outer membrane Ng protein, MtrE, with various immunostimulatory adjuvant molecules (IAMs) in the VesiVax® liposomal platform. We will characterize the immunogenicity of these VesiVax®-MtrE-IAM formulations in mice, and select for the best candidates to be further evaluated in a novel mouse upper reproductive tract Ng infection model. These studies will elucidate the immunological profile in a vaccine that will correlate with protective immunity against Ng.